80%Confidence
0Views
FDASource
2026-04-20Date
Summary
Teva's second clonidine patch recall for the same CGMP issue indicates a pattern of non-compliance. This could lead to more stringent FDA oversight and impact its ability to launch new products.
Actionable: Monitor Teva for any updates on FDA warnings or consent decrees related to these deviations.
AI Confidence: 80%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionWithin U.S
productClonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx Only, Manufactured by: Actavis Laboratories
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now